Beije et al [42] designed a CRC-specific 21-gene NGS panel and plasma samples from 12 mCRC patients analyzed by this panel showed calculated sensitivity of 50% and specificity of 87.5% in KRAS mutation detection. The gene discussed is KRAS; the disease is colorectal carcinoma.